Meeting
2018 ASCO Annual Meeting
A randomized phase II/III trial of conventional paclitaxel and carboplatin (cTC) versus dose-dense paclitaxel and carboplatin (ddTC), with or without bevacizumab (Bmab), for stage IVb, recurrent, or persistent cervical cancer (CC): Japan Clinical Oncology Group study (JCOG1311).
Authors
Ryo Kitagawa
Department of Gynecology and Obstetrics, Tohoku Medical and Pharmaceutical University, Miyagi, Japan
Ryo Kitagawa , Mitsuya Ishikawa , Taro Shibata , Kenichi Miyamoto , Hiroaki Kobayashi , Takashi ONDA , Munetaka Takekuma , Fumiaki Takahashi , Harushige Yokota , Michihiro Tanikawa , Mika Mizuno , Tetsuro Oishi , Yoichi Aoki , Shin Nishio , Takashi Iwata , Nobuo Yaegashi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Cervical Cancer
Clinical Trial Registration Number
000019191
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS5603)
DOI
10.1200/JCO.2018.36.15_suppl.TPS5603
Abstract #
TPS5603
Poster Bd #
328b
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A randomized phase II/III trial of conventional paclitaxel and carboplatin with/without bevacizumab versus dose-dense paclitaxel and carboplatin with/without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): Results of the phase II part.
First Author: Mitsuya Ishikawa
Poster
2018 ASCO Annual Meeting
Preliminary results from CECILIA, an open-label global safety study of bevacizumab (BEV), carboplatin (C) and paclitaxel (P) therapy for metastatic, recurrent or persistent cervical cancer (CC).
First Author: Andres Redondo
Poster
2023 ASCO Annual Meeting
SHR-1701 in combination with platinum-based chemotherapy and BP102 (a bevacizumab biosimilar) for persistent, recurrent, or metastatic cervical cancer: Data from a phase 1b/3 study.
First Author: Jihong Liu
Poster
2023 ASCO Annual Meeting
The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study.
First Author: Jianqing Zhu